NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

  • End date
    Jan 5, 2023
  • participants needed
  • sponsor
    Nektar Therapeutics
Updated on 5 April 2022
multiple myeloma
hodgkin's disease
white blood cells
neutrophil count
proteasome inhibitor
primary disease
refractory multiple myeloma
immunotherapeutic agent
immunomodulatory imide drug


Patients will receive intravenous (IV) NKTR-255 in 21 or 28 day treatment cycles. During the Part 1 dose escalation portion of the trial, patients will either receive NKTR-255 as monotherapy, NKTR-255 administered as a doublet with daratumumab subcutaneous (DARZALEX FASPRO TM), or NKTR-255 administered as a doublet with rituximab. After determination of the recommended Phase 2 dose (RP2D) of NKTR-255, NKTR-255 will be evaluated in Part 2. During the Part 2 dose expansion portion of the trial, patients will either receive NKTR-255 as monotherapy, NKTR-255 administered as a doublet with daratumumab subcutaneous (DARZALEX FASPRO TM), or NKTR-255 administered as a doublet with rituximab.

This is a Phase 1 study to evaluate safety and tolerability of NKTR-255 alone and in combination with daratumumab or rituximab.


NKTR-255 is a cytokine that is designed to regulate T and natural killer cell activation, proliferation and promote their anti-tumor effects.

This is a Phase 1, open-label, multi-center, dose escalation, dose expansion, safety follow-up, and survival follow-up of NKTR-255 as a single agent and NKTR-255 in combination with DARZALEX FASPRO TM or rituximab. Study treatment is defined as any investigational treatment(s) or marketed product(s), intended to be administered to a study patient according to the study enrollment.

Part 1 will enroll relapsed/refractory multiple myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) patients. In Part 2, Cohort A will enroll NHL patients who have progressed on a chimeric antigen receptor T-cell (CAR-T) product, Cohort B will enroll MM patients who previously received daratumumab and other anti-CD38 therapies to receive NKTR-255 alone and/or in combination with daratumumab, and Cohort C will enroll indolent Non-Hodgkin's Lymphoma (iNHL) patients who previously received rituximab and other therapies to receive NKTR-255 alone and/or in combination with rituximab.

Condition Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma
Treatment Rituximab, Daratumumab, NKTR-255, NKTR-255 Q21
Clinical Study IdentifierNCT04136756
SponsorNektar Therapeutics
Last Modified on5 April 2022


Yes No Not Sure

Inclusion Criteria

Patients must have relapsed or refractory MM or NHL with no available therapies that would confer clinical benefit for their primary disease
For MM patients, measurable relapsed or refractory MM as defined by the IMWG Criteria (Kumar, 2016) following treatment with at least 3 lines of therapy with no other available treatment that would confer benefit
For NHL patients, measurable or detectable disease according to International Myeloma Working Group (IMWG) and the Lugano Classification. Extranodal NHL disease that is measurable by fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging only is allowed
Patient has the following laboratory test results during Screening
Estimated glomerular filtration rate (eGFR) ≥ 40 mL/min/1.73 m2
Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2
Absolute neutrophil count (ANC) or absolute granulocyte count (AGC) ≥ 1000/µL
Platelets ≥ 30,000/µL
Hemoglobin ≥ 8g/dL
Absolute lymphocytes ≥ 500/µL
Patients are eligible who also meet all the following criteria in these
Leukocytes ≥ 3000/µL
cohorts of Part 2
NKTR-255 Monotherapy NHL Group Only
Patients with NHL who received a commercially approved CD19 CAR-T product and had PD. The first dose of NKTR-255 will be administered within 30 days of the PD
NKTR-255 with Daratumumab MM Group Only
Patients with MM must have had previous exposure to proteasome inhibitor, immunomodulatory agent (IMiD), and anti-CD38 therapy
Patients who previously received daratumumab or other anti-CD38 therapies must have at least 3 months washout
NKTR-255 with Rituximab Group iNHL Group Only
Patients with relapsed or refractory iNHL who previously progressed during or following 1 or more prior systemic rituximab-containing (or another treatment with an anti-CD20 antibody-containing) regimens for lymphoma

Exclusion Criteria

Patients who have an active, known, or suspected autoimmune disease
Any treatment-related neurotoxicity or cytokine release syndrome (CRS) prior to enrollment into the study should return to baseline before NKTR-255 treatment
Active central nervous system (CNS) involvement with NHL
Patients who have been previously treated with prior interleukin-2 or interleukin-15
Patients who received daratumumab or other anti-CD38 therapies previously must have 3 months washout
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note